Monoclonal antibodies reactive with immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans

Clinical and Diagnostic Laboratory Immunology

Volumn 10, Issue 5, 2003, Pages 903-909

  Brandt, Suzanne ^a   Thorkildson, Peter ^a   Kozel, Thomas R ^a  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLUCURONOXYLOMANNAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY F12D2; POLYCLONAL ANTIBODY; POLYSACCHARIDE; UNCLASSIFIED DRUG;

ACETYLATION; ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY REACTION; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; HYBRIDOMA; IMMUNIZATION; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; SCREENING TEST; SEROTYPE;

ANIMALS; ANTIBODIES, FUNGAL; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, FUNGAL; CRYPTOCOCCUS NEOFORMANS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; HYBRIDOMAS; MICE; POLYSACCHARIDES;

EID: 0141563818     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/CDLI.10.5.903-909.2003     Document Type: Article

References (46)

1. Belay, T., and R. Cherniak. 1995. Determination of antigen binding specificities of Cryptococcus neoformans factor sera by enzyme-linked immunosorbent assay. Infect. Immun. 63:1810-1819.
2. Belay, T., R. Cherniak, T. R. Kozel, and A. Casadevall. 1997. Reactivity patterns and epitope specificities of anti-Cryptococcus neoformans monoclonal antibodies by enzyme-linked immunosorbent assay and dot enzyme assay. Infect. Immun. 65:718-728.
3. Berry, D. S., F. Lynn, C.-H. Lee, C. E. Frasch, and M. C. Bash. 2002. Effect of O acetylation of Neisseria meningitidis serogroup A capsular polysaccharide on development of functional immune responses. Infect. Immun. 70:3707-3713.
4. Bhattacharjee, A. K., J. E. Bennett, and C. P. J. Glaudemans. 1984. Capsular polysaccharides of Cryptococcus neoformans. Rev. Infect. Dis. 6:619-624.
5. Casadevall, A., M. DeShaw, M. Fan, F. Dromer, T. R. Kozel, and L. Pirofski. 1994. Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan. Infect. Immun. 62:3864-3872.
6. Casadevall, A., J. Mukherjee, S. J. N. Devi, R. Schneerson, J. B. Robbins, and M. D. Scharff. 1992. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J. Infect. Dis. 165:1086-1093.
7. Cherniak, R., L. C. Morris, B. C. Anderson, and S. A. Meyer. 1991. Facilitated isolation, purification, and analysis of glucuronoxylomannan of Cryptococcus neoformans. Infect. Immun. 59:59-64.
8. Cherniak, R., E. Reiss, M. E. Slodki, R. D. Plattner, and S. O. Blumer. 1980. Structure and antigenic activity of the capsular polysaccharide of Cryptococcus neoformans. Mol. Immunol. 17:1025-1032.
9. Cherniak, R., E. Reiss, and S. H. Turner. 1982. A galactoxylomannan antigen of Cryptococcus neoformans serotype A. Carbohydr. Res. 103:239-250.
10. Cherniak, R., H. Valafar, L. C. Morris, and F. Valafar. 1998. Cryptococcus neoformans chemotyping by quantitative analysis of 1H nuclear magnetic resonance spectra of glucuronoxylomannans with a computer-simulated artificial neural network. Clin. Diagn. Lab. Immunol. 5:146-159.
11. Dromer, F., J. Charreire, A. Contrepois, C. Carbon, and P. Yeni. 1987. Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. Infect. Immun. 55:749-752.
12. Duro, R. M., D. Netski, P. Thorkildson, and T. R. Kozel. 2003. Contribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan. Clin. Diagn. Lab. Immunol. 10:252-258.
13. Eckert, T. F., and T. R. Kozel. 1987. Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide. Infect. Immun. 55:1895-1899.
14. Falugi, F., R. Petracca, M. Mariani, E. Luzzi, S. Mancianti, V. Carinci, M. L. Melli, O. Finco, A. Wack, A. Di Tommaso, M. T. De Magistris, P. Costantino, G. Del Giudice, S. Abrignani, R. Rappuoli, and G. Grandi. 2001. Rationally designed strings of promiscuous CD4(+) T cell epitopes provide help to Haemophilus influenzae type b oligosaccharide: a model for new conjugate vaccines. Eur. J. Immunol. 31:3816-3824.
15. Fattom, A. I., J. Sanvar, L. Basham, S. Ennifar, and R. Naso. 1998. Antigenic determinants of Staphylococcus aureus type 5 and type 8 capsular polysaccharide vaccines. Infect. Immun. 66:4588-4592.
16. Goldman, D. L., S. C. Lee, and A. Casadevall. 1995. Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody. Infect. Immun. 63:3448-3453.
17. Granger, D. L., J. R. Perfect, and D. T. Durack. 1985. Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxide. J. Clin. Investig. 76:508-516.
18. Grinsell, M., L. C. Weinhold, J. E. Cutler, Y. Han, and T. R. Kozel. 2001. In vivo clearance of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans: a critical role for tissue macrophages. J. Infect. Dis. 184:479-487.
19. Grusby, M. J., H. Auchincloss, Jr., R. Lee, R. S. Johnson, J. P. Spencer, M. Zijlstra, R. Jaenisch, V. E. Papaioannou, and L. H. Glimcher. 1993. Mice lacking major histocompatibility complex class I and class II molecules. Proc. Natl. Acad. Sci. USA 90:3913-3917.
20. Ikeda, R., T. Shinoda, Y. Fukazawa, and L. Kaufman. 1982. Antigenic characterization of Cryptococcus neoformans serotypes and its application to serotyping of clinical isolates. J. Clin. Microbiol. 16:22-29.
21. Kozel, T. R., and J. Cazin, Jr. 1972. Immune response to Cryptococcus neoformans soluble polysaccharide. I. Serological assay for antigen and antibody. Infect. Immun. 5:35-41.
22. Kozel, T. R., B. C. H. deJong, M. M. Grinsell, R. S. MacGill, and K. K. Wall. 1998. Characterization of anti-capsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsule. Infect. Immun. 66:1538-1546.
23. Kozel, T. R., and J. L. Follette. 1981. Opsonization of encapsulated Cryptococcus neoformans by specific anticapsular antibody. Infect. Immun. 31:978-984.
24. Kozel, T. R., and E. C. Gotschlich. 1982. The capsule of Cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages. J. Immunol. 129:1675-1680.
25. Kozel, T. R., S. M. Levitz, F. Dromer, M. A. Gates, P. Thorkildson, and G. Janbon. 2003. Antigenic and biological characteristics of mutant strains of Cryptococcus neoformans lacking capsular O acetylation or xylosyl side chains. Infect. Immun. 71:2868-2875.
26. Lane, R. D., R. S. Crissman, and M. F. Lachman. 1984. Comparison of polyethylene glycols as fusogens for producing lymphocyte-myeloma hybrids. J. Immunol. Methods 72:71-76.
27. Leinonen, M., and C. E. Frasch. 1982. Class-specific antibody response to group B Neisseria meningitidis capsular polysaccharide: use of polylysine precoating in an enzyme-linked immunosorbent assay. Infect. Immun. 38:1203-1207.
28. Lendvai, N., A. Casadevall, Z. Liang, D. L. Goldman, J. Mukherjee, and L. S. Zuckier. 1998. Effect of immune mechanisms on the pharmacokinetics and organ distribution of cryptococcal polysaccharide. J. Infect. Dis. 177:1647-1659.
29. Lüderitz, O., A. M. Staub, and O. Westphal. 1966. Immunochemistry of O and R antigens of Salmonella and related Enterobacteriaceae. Bacteriol. Rev. 30:192-255.
30. MacGill, T. C., R. S. MaeGill, A. Casadevall, and T. R. Kozel. 2000. Biological correlates of capsular (quellung) reactions of Cryptococcus neoformans. J. Immunol. 164:4835-4842.
31. MacGill, T. C., R. S. MacGill, and T. R. Kozel. 2001. Capsular reaction of Cryptococcus neoformans with polyspecific and oligospecific polyclonal anticapsular antibodies. Infect. Immun. 69:1189-1191.
32. McNeely, T. B., J. M. Staub, C. M. Rusk, M. J. Blum, and J. J. Donnelly. 1998. Antibody responses to capsular polysaccharide backbone and O-acetate side groups of Streptococcus pneumoniae type 9V in humans and rhesus macaques. Infect. Immun. 66:3705-3710.
33. Mukherjee, J., M. D. Scharif, and A. Casadevall. 1992. Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect. Immun. 60:4534-4541.
34. Netski, D., and T. R. Kozel. 2002. Fc-dependent and Fc-independent opsonization of Cryptococcus neoformans by anticapsular monoclonal antibodies: importance of epitope specificity. Infect. Immun. 70:2812-2819.
35. Orskov, F., I. Orskov, A. Sutton, R. Schneerson, W. Lin, W. Egan, G. E. Hoff, and J. B. Robbins. 1979. Form variation in Escherichia coli K1: determined by O-acetylation of the capsular polysaccharide. J. Exp. Med. 149:669-685.
36. Richmond, P., R. Borrow, J. Findlow, S. Martin, C. Thornton, K. Cartwright, and E. Miller. 2001. Evaluation of de-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and de-O-acetylated serogroup C strains. Infect. Immun. 69:2378-2382.
37. Savoy, A. C., D. M. Lupan, P. B. Manalo, J. S. Roberts, A. M. Schlageter, L. C. Weinhold, and T. R. Kozel. 1997. Acute lethal toxicity following passive immunization for treatment of murine cryptococcosis. Infect. Immun. 65:1800-1807.
38. Schlageter, A. M., and T. R. Kozel. 1990. Opsonization of Cryptococcus neoformans by a family of isotype-switch variant antibodies specific for the capsular polysaccharide. Infect. Immun. 58:1914-1918.
39. Segal, D. M. 1995. Antibody detection and preparation, p. 2.0.1-2.13.16. In J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober (ed.), Current protocols in immunology. John Wiley and Sons, Inc., New York, N.Y.
40. Sercarz, E. E., P. V. Lehmann, A. Ametani, G. Benichou, A. Miller, and K. Moudgil. 1993. Dominance and crypticity of T cell antigenic determinants. Annu. Rev. Immunol. 11:729-766.
41. Spiropulu, C., R. A. Eppard, E. Otteson, and T. R. Kozel. 1989. Antigenic variation within serotypes of Cryptococcus neoformans detected by monoclonal antibodies specific for the capsular polysaccharide. Infect. Immun. 57:3240-3242.
42. Sundstrom, J. B., and R. Cherniak. 1992. The glucuronoxylomannan of Cryptococcus neoformans serotype A is a type 2 T-independent antigen. Infect. Immun. 60:4080-4087.
43. Szu, S. C., X. R. Li, A. L. Stone, and J. B. Robbins. 1991. Relation between structure and immunologic properties of the Vi capsular polysaccharide. Infect. Immun. 59:4555-4561.
44. Turner, S. H., and R. Cherniak. 1991. Multiplicity in the structure of the glucuronoxylomannan of Cryptococcus neoformans, p. 123-142. In J. P. Latgé and D. Boucias (ed.), Fungal cell wall and immune response. Springer-Verlag, Berlin, Germany.
45. Vecchiarelli, A., and A. Casadevall. 1998. Antibody-mediated effects against Cryptococcus neoformans: evidence for interdependency and collaboration between humoral and cellular immunity. Res. Immunol. 149:321-333.
46. Wilson, D. E., J. E. Bennett, and J. W. Bailey. 1968. Serologic grouping of Cryptococcus neoformans. Proc. Soc. Exp. Biol. Med. 127:820-823.